Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue

Patent metadata

Field	Value
Publication number	US-9993504-B2
Application number	US-201414782070-A
Country	US
Kind code	B2
Filing date	Apr 2, 2014
Priority date	Apr 5, 2013
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR-primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.

First claim

The invention claimed is:

1. A method for generating articular-like, non-hypertrophic chondrocyte cells, cartilage-like tissue, cartilage, or a combination thereof, the method comprising:
a. culturing a CD56 + and PDGFRalpha + primitive streak-like mesoderm population with a paraxial mesoderm specifying cocktail comprising:
i. an FGF agonist; and
ii. an BMP inhibitor

to generate a CD73+CD104+, or CD73+PDGFRbeta+, or CD73+CD105+ PDGFRbeta+ paraxial mesoderm population;
b. culturing the paraxial mesoderm population at a high cell density with a TGFbeta agonist to produce a high cell density, Sox9 + , collagen 2 + , chondrocyte precursor population; and
c. further culturing the high cell density, Sox9 + , collagen 2 + chondrocyte precursor population with the TGFbeta agonist, in the absence of a BMP or PDGF agonist, for at least 10 days to produce an articular non-hypertrophic chondrocyte cells, cartilage-like tissue and/or cartilage.

2. The method of claim 1 , wherein the CD56 + and PDGFRalpha + primitive streak-like mesoderm population is derived from a human embryonic stem cell population (hESC) or a human induced pluripotent stem cell population (iPSC).

3. The method of claim 1 , wherein the FGF agonist is selected from the group consisting of FGF2, FGF4, FGF9, FGF19, FGF21, FGF3, FGF5, FGF6, FGF8a, FGF16, FGF17, FGF18, FGF20 and FGF23.

4. The method of claim 1 , wherein the BMP inhibitor is selected from the group consisting of Chordin, soluble BMPR1a, soluble BMPR1b, Noggin, LDN-193189, and Dorsomorphin.

5. The method of claim 1 , wherein the paraxial mesoderm specifying cocktail further comprises a Wnt inhibitor.

6. The method of claim 5 , wherein the Wnt inhibitor is selected from the group consisting of DKK1, IWP2, and XAV939.

7. The method of claim 1 , wherein the paraxial mesoderm specifying cocktail further comprises a TGFbeta inhibitor.

8. The method of claim 7 , wherein the TGFbeta inhibitor is SB431524.

9. The method of claim 1 wherein the paraxial mesoderm population is comprised in embryoid bodies, monolayer culture and/or a combination thereof.

10. The method of claim 1 , wherein the paraxial mesoderm population also expresses transcription factors Meox1 and Nkx3.2 and is negative for Nkx2.5.

11. The method of claim 1 , wherein the Sox9 + , collagen 2 + chondrocyte precursor population is further cultured with the TGFbeta agonist until lubricin, cartilage intermediate layer protein 2 (CILP2), or both are expressed.

12. The method of claim 1 , wherein the further culturing the high cell density, Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta agonist is performed in serum free media.

13. The method of claim 1 , further comprising administering the articular like, non-hypertrophic chondrocyte cells to a subject.

14. The method of claim 1 , further comprising administering the cartilage-like tissue to a subject.

15. The method of claim 1 , further comprising administering the cartilage to a subject.

16. The method of claim 13 , wherein the subject has osteoarthritis, osteochondritis dissecans, polychondritis, other chondropathies, or joint injuries affecting the cartilage, to ameliorate symptoms and/or treat osteoarthritis, osteochondritis dissecans, polychondritis, other chondropathies, or joint injuries affecting the cartilage.

17. The method of claim 14 , wherein the subject has osteoarthritis, osteochondritis dissecans, polychondritis, other chondropathies, or joint injuries affecting the cartilage, to ameliorate symptoms and/or treat osteoarthritis, osteochondritis dissecans, polychondritis, other chondropathies, or joint injuries affecting the cartilage.

18. The method of claim 15 , wherein the subject has osteoarthritis, osteochondritis dissecans, polychondritis, other chondropathies, or joint injuries affecting the cartilage, to ameliorate symptoms and/or treat osteoarthritis, osteochondritis dissecans, polychondritis, other chondropathies, or joint injuries affecting the cartilage.

19. A method of testing candidate chondrogenic modulating substances selected from the group consisting of a factor isolated from a subject with diseased cartilage or bone, a factor isolated from a fat pad in a joint of a subject with arthritis, a factor isolated from a fat pad in a joint of an obese subject, and a factor isolated from a fat pad in a joint of a healthy subject, the method comprising:
a. carrying out the method of claim 1 , wherein said test substance is included in any one or more of the culture steps of the method of claim 1 ;
b. assessing the effect of the test substance on chondrocyte proliferation, maintenance and/or differentiation compared to a control population generated in the absence of test substance; and
c. identifying the test substance as a candidate chondrogenic modulating substance if the test substance increases or decreases proliferation, and/or affects chondrocyte maintenance or differentiation compared to the control.

Assignees

• Univ Health Network

Inventors

• Keller Gordon
• Craft April M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P19/10

  for osteoporosis · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title